286 studies found for:    leukemia AND (women OR woman OR female)
Show Display Options
Rank Status Study
21 Recruiting Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia
Condition: Untreated Adult Acute Myeloid Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Idarubicin;   Other: Laboratory Biomarker Analysis;   Drug: Vorinostat
22 Completed Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia
Condition: Leukemia
Intervention: Drug: docetaxel
23 Active, not recruiting
Has Results
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
Condition: Leukemia
Interventions: Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: gemtuzumab ozogamicin;   Drug: mitoxantrone hydrochloride
24 Active, not recruiting Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Condition: Leukemia
Interventions: Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
25 Active, not recruiting S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Drug: arsenic trioxide;   Drug: gemtuzumab ozogamicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: tretinoin
26 Active, not recruiting Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Condition: Leukemia
Interventions: Biological: rituximab;   Drug: fludarabine phosphate
27 Active, not recruiting Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
Conditions: Leukemia, Myelocytic, Acute;   Leukemia, Lymphocytic, Acute;   Leukemia, Myeloid, Chronic;   Myelodysplastic Syndromes
Interventions: Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Sirolimus
28 Terminated
Has Results
Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndrome
Intervention: Drug: deferoxamine
29 Completed A Multicentre, Randomised, Double-blind, Placebo-controlled Proof of Concept Study to Compare the Efficacy and Safety of r-hLIF (Emfilermin) for Improving Embryo Implantation Following in Vitro Fertilization (IVF) and Embryo Transfer (ET) in Women With Recurrent Implantation Failure
Condition: Infertility, Implantation Failure.
Intervention: Drug: Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)
30 Recruiting Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Drug: Vincristine Sulfate
31 Recruiting Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Conditions: Adult T Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Contiguous Adult Lymphoblastic Lymphoma;   Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Bortezomib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
32 Active, not recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: B-cell Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: doxorubicin hydrochloride;   Radiation: 3-dimensional conformal radiation therapy;   Drug: cytarabine;   Drug: dexamethasone;   Drug: pegaspargase;   Drug: methotrexate;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: cyclophosphamide;   Drug: thioguanine;   Drug: vincristine sulfate
33 Recruiting Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia;   Adult Acute Monoblastic Leukemia;   Adult Acute Monocytic Leukemia;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With Maturation;   Adult Acute Myeloid Leukemia With Minimal Differentiation;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Myeloid Leukemia Without Maturation;   Adult Acute Myelomonocytic Leukemia;   Adult Erythroleukemia;   Adult Pure Erythroid Leukemia;   Childhood Acute Erythroid Leukemia;   Childhood Acute Megakaryoblastic Leukemia;   Childhood Acute Monoblastic Leukemia;   Childhood Acute Monocytic Leukemia;   Childhood Acute Myeloid Leukemia With Maturation;   Childhood Acute Myeloid Leukemia Without Maturation;   Childhood Acute Myelomonocytic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Myeloid Neoplasm
Interventions: Drug: Asparaginase;   Drug: Bortezomib;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Sorafenib Tosylate
34 Active, not recruiting Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Asparaginase;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Hydrocortisone Sodium Succinate;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Vincristine Sulfate
35 Active, not recruiting Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Biological: Alemtuzumab;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide Phosphate;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Melphalan;   Drug: Mercaptopurine;   Drug: Methotrexate;   Biological: Pegfilgrastim;   Other: Pharmacological Study;   Drug: Tacrolimus;   Drug: Vincristine Sulfate
36 Recruiting Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation
Conditions: Myelodysplastic Syndrome RAEB 2;   Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome RAEB 1
Interventions: Procedure: Allogeneic HSC Transplantation;   Drug: Lupron;   Drug: 18F FLT;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Tacrolimus;   Radiation: Total Body Irradiation
37 Completed
Has Results
S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML
Condition: Leukemia
Interventions: Drug: gemtuzumab ozogamicin;   Other: observation;   Drug: Cytosine arabinoside;   Drug: Daunomycin
38 Recruiting Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Condition: Acute Lymphoblastic Leukaemia
Interventions: Drug: VP16;   Radiation: TBI;   Drug: Thiotepa;   Drug: Treosulfan;   Drug: Fludarabine;   Drug: Busulfan
39 Active, not recruiting
Has Results
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Phase of Disease
Interventions: Drug: Dasatinib;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis
40 Active, not recruiting Preservation of Ovarian Function After Hematopoietic Cell Transplant
Conditions: Multiple Myeloma;   Non-Hodgkin Lymphoma;   Hodgkin Disease;   Acute Myeloid Leukemia;   Myeloproliferative Disorders
Interventions: Drug: Leuprolide;   Biological: hematopoietic cell transplant;   Biological: reduced intensity allogeneic HCT

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years